First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
Journal
The Lancet Oncology
Journal Volume
10
Journal Issue
11
Pages
1102-1110
Date Issued
2009
Author(s)
Abstract
Non-small-cell lung cancer (NSCLC) is an increasing global challenge, especially in low-income countries. Most guidelines for the management of advanced-stage NSCLC have limited effect in countries with resource constraints. Following a systematic literature search, we present an overview of the management of advanced-stage NSCLC in the first-line setting, discuss resources required for systemic therapy, and provide treatment recommendations stratified to four resources levels. Treatment guidelines appropriate for different resource levels offer a realistic approach to management of advanced-stage NSCLC, by recognising the limitations of a particular health-care system. Although there are many barriers to cancer control in low-resource countries, these can be overcome by using measures that are culturally appropriate, economically feasible, and evidence-based. Initiatives include strategic planning, tobacco control, training of health-care workers, access to therapeutic agents, acquisition of information, public education, and alliances with established institutions and international organisations. ? 2009 Elsevier Ltd. All rights reserved.
SDGs
Other Subjects
bevacizumab; carboplatin; cetuximab; cisplatin; docetaxel; erlotinib; etoposide; gefitinib; gemcitabine; ifosfamide; irinotecan; mitomycin; navelbine; paclitaxel; pemetrexed; placebo; taxane derivative; teniposide; vinblastine; Vinca alkaloid; vindesine; advanced cancer; Asia; cancer survival; clinical trial; drug megadose; drug protein binding; drug response; elderly care; health care system; health program; human; low drug dose; lung non small cell cancer; maintenance therapy; multiple cycle treatment; nephrotoxicity; practice guideline; primary health care; priority journal; resource allocation; review; thrombocytopenia; treatment duration; vomiting; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Congresses as Topic; Cost-Benefit Analysis; Developing Countries; Drug Costs; Evidence-Based Medicine; Guideline Adherence; Health Care Costs; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Treatment Outcome
Publisher
Lancet Publishing Group
Type
Review